Pyxis Oncology to webcast updated Phase 1 MICVO monotherapy data in recurrent/metastatic head and neck cancer

MICVO holds FDA Fast Track status for adults whose disease progressed after platinum chemotherapy and anti-PD-(L)1 therapy.

Management will outline how the latest findings shape the program’s risk-benefit profile in a hard-to-treat setting.

The company will also frame next clinical development steps, a key input for timelines, partnering prospects, and future funding needs.

Pyxis Oncology scheduled a Sept. 9, 2026 webcast to present updated Phase 1 monotherapy data for micvotabart pelidotin in 2L+ R/M HNSCC.

Results have not yet been presented; the update will be delivered during the webcast.